Erythropoietic protoporphyria and afamelanotide: a patient’s perspective
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llad346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Marese O'Reilly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Photobiology Unit. Hauptthemen laut MEDLINE: Protoporphyria, Erythropoietic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
The patient explores the profound impact of erythropoietic protoporphyria (EPP) on her life to date. The clinician’s comment reviews the symptoms and diagnostic criteria for EPP, as well as the novel treatment afamelanotide for EPP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Photobiology Unit.
- Scottish Cutaneous Porphyria Service, Ninewells Hospital, Dundee, UK.
Zitieren
APA
O'Reilly, M., McGuire, V. A., & Dawe, R. S. (2024). Erythropoietic protoporphyria and afamelanotide: a patient’s perspective. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad346
Vancouver
O'Reilly M, McGuire VA, Dawe RS. Erythropoietic protoporphyria and afamelanotide: a patient’s perspective. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llad346
BibTeX
@article{OReilly2024,
author = {O'Reilly, Marese and McGuire, Vicky A and Dawe, Robert S},
title = {Erythropoietic protoporphyria and afamelanotide: a patient’s perspective},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llad346}
}
EUVIMED